Cargando…

Ezrin expression combined with MSI status in prognostication of stage II colorectal cancer

Currently used factors predicting disease recurrence in stage II colorectal cancer patients are not optimal for risk stratification. Thus, new biomarkers are needed. In this study the applicability of ezrin protein expression together with MSI status and BRAF mutation status were tested in predictin...

Descripción completa

Detalles Bibliográficos
Autores principales: Slik, Khadija, Kurki, Samu, Korpela, Taina, Carpén, Olli, Korkeila, Eija, Sundström, Jari
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5617236/
https://www.ncbi.nlm.nih.gov/pubmed/28953975
http://dx.doi.org/10.1371/journal.pone.0185436
_version_ 1783266964323434496
author Slik, Khadija
Kurki, Samu
Korpela, Taina
Carpén, Olli
Korkeila, Eija
Sundström, Jari
author_facet Slik, Khadija
Kurki, Samu
Korpela, Taina
Carpén, Olli
Korkeila, Eija
Sundström, Jari
author_sort Slik, Khadija
collection PubMed
description Currently used factors predicting disease recurrence in stage II colorectal cancer patients are not optimal for risk stratification. Thus, new biomarkers are needed. In this study the applicability of ezrin protein expression together with MSI status and BRAF mutation status were tested in predicting disease outcome in stage II colorectal cancer. The study population consisted of 173 stage II colorectal cancer patients. Paraffin-embedded cancer tissue material from surgical specimens was used to construct tissue microarrays (TMAs) with next-generation technique. The TMA-slides were subjected to following immunohistochemical stainings: MLH1, MSH2, MSH6, PMS2, ezrin and anti-BRAF V600E antibody. The staining results were correlated with clinicopathological variables and survival. In categorical analysis, high ezrin protein expression correlated with poor disease-specific survival (p = 0.038). In univariate analysis patients having microsatellite instabile / low ezrin expression tumors had a significantly longer disease-specific survival than patients having microsatellite stable / high ezrin expression tumors (p = 0.007). In multivariate survival analysis, the presence of BRAF mutation was associated to poor overall survival (p = 0.028, HR 3.29, 95% CI1.14–9.54). High ezrin protein expression in patients with microsatellite stable tumors was linked to poor disease-specific survival (p = 0.01, HR 5.68, 95% CI 1.53–21.12). Ezrin protein expression is a promising biomarker in estimating the outcome of stage II colorectal cancer patients. When combined with microsatellite status its ability in predicting disease outcome is further improved.
format Online
Article
Text
id pubmed-5617236
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-56172362017-10-09 Ezrin expression combined with MSI status in prognostication of stage II colorectal cancer Slik, Khadija Kurki, Samu Korpela, Taina Carpén, Olli Korkeila, Eija Sundström, Jari PLoS One Research Article Currently used factors predicting disease recurrence in stage II colorectal cancer patients are not optimal for risk stratification. Thus, new biomarkers are needed. In this study the applicability of ezrin protein expression together with MSI status and BRAF mutation status were tested in predicting disease outcome in stage II colorectal cancer. The study population consisted of 173 stage II colorectal cancer patients. Paraffin-embedded cancer tissue material from surgical specimens was used to construct tissue microarrays (TMAs) with next-generation technique. The TMA-slides were subjected to following immunohistochemical stainings: MLH1, MSH2, MSH6, PMS2, ezrin and anti-BRAF V600E antibody. The staining results were correlated with clinicopathological variables and survival. In categorical analysis, high ezrin protein expression correlated with poor disease-specific survival (p = 0.038). In univariate analysis patients having microsatellite instabile / low ezrin expression tumors had a significantly longer disease-specific survival than patients having microsatellite stable / high ezrin expression tumors (p = 0.007). In multivariate survival analysis, the presence of BRAF mutation was associated to poor overall survival (p = 0.028, HR 3.29, 95% CI1.14–9.54). High ezrin protein expression in patients with microsatellite stable tumors was linked to poor disease-specific survival (p = 0.01, HR 5.68, 95% CI 1.53–21.12). Ezrin protein expression is a promising biomarker in estimating the outcome of stage II colorectal cancer patients. When combined with microsatellite status its ability in predicting disease outcome is further improved. Public Library of Science 2017-09-27 /pmc/articles/PMC5617236/ /pubmed/28953975 http://dx.doi.org/10.1371/journal.pone.0185436 Text en © 2017 Slik et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Slik, Khadija
Kurki, Samu
Korpela, Taina
Carpén, Olli
Korkeila, Eija
Sundström, Jari
Ezrin expression combined with MSI status in prognostication of stage II colorectal cancer
title Ezrin expression combined with MSI status in prognostication of stage II colorectal cancer
title_full Ezrin expression combined with MSI status in prognostication of stage II colorectal cancer
title_fullStr Ezrin expression combined with MSI status in prognostication of stage II colorectal cancer
title_full_unstemmed Ezrin expression combined with MSI status in prognostication of stage II colorectal cancer
title_short Ezrin expression combined with MSI status in prognostication of stage II colorectal cancer
title_sort ezrin expression combined with msi status in prognostication of stage ii colorectal cancer
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5617236/
https://www.ncbi.nlm.nih.gov/pubmed/28953975
http://dx.doi.org/10.1371/journal.pone.0185436
work_keys_str_mv AT slikkhadija ezrinexpressioncombinedwithmsistatusinprognosticationofstageiicolorectalcancer
AT kurkisamu ezrinexpressioncombinedwithmsistatusinprognosticationofstageiicolorectalcancer
AT korpelataina ezrinexpressioncombinedwithmsistatusinprognosticationofstageiicolorectalcancer
AT carpenolli ezrinexpressioncombinedwithmsistatusinprognosticationofstageiicolorectalcancer
AT korkeilaeija ezrinexpressioncombinedwithmsistatusinprognosticationofstageiicolorectalcancer
AT sundstromjari ezrinexpressioncombinedwithmsistatusinprognosticationofstageiicolorectalcancer